Sustained MRD negativity predicts outcomes post transplant in myeloma: a real world study Presented at EHA2018 Michael Austin Haematology SpR, South West London Deanery; 2018

Special thanks to

The project MRD negativity at 3 months post autologous stem cell transplant (ASCT) is known to be a good prognostic marker in myeloma Does sustained MRD negativity at 1 year post-ASCT predict outcomes as well? Retrospective study 368 consecutive ASCT The Royal Marsden from 2011 to 2015 MRD data collected at 3 and 12 months post-ASCT

Results Sustained MRD negativity between 3 and 12 months post transplant predicts excellent outcomes 1st transplant 2nd transplant

The poster

Acknowledgments The patients The UK Myeloma Forum and The Binding Site The myeloma and transplant teams at RMH

Thank you